Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan

References

• DuchnowskaR, LoiblS, JassemJ. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat. Rev.67, 71–77 (2018).
   PubMed Web of Science ®Google Scholar
• HosonagaM, SayaH, ArimaY. Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev.39(3), 711–720 (2020).
   PubMed Web of Science ®Google Scholar
• RamakrishnaN, TeminS, ChandarlapatySet al.Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO Clinical Practice Guideline update. J. Clin. Oncol.36(27), 2804–2807 (2018).
   PubMed Web of Science ®Google Scholar
• RostamiR, MittalS, RostamiP, TavassoliF, JabbariB. Brain metastasis in breast cancer: a comprehensive literature review. J. Neurooncol.127(3), 407–414 (2016).
   PubMed Web of Science ®Google Scholar
• SimmonsC, RaysonD, JoyAAet al.Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines. Ther. Adv. Med. Oncol.14, 17588359211066677 (2022).
   Web of Science ®Google Scholar
• SperdutoPW, MeskoS, LiJet al.Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J. Clin. Oncol.38(32), 3773–3784 (2020).
   PubMed Web of Science ®Google Scholar
• VogelbaumMA, BrownPD, MessersmithHet al.Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J. Clin. Oncol.40(5), 492–516 (2022).
   PubMed Web of Science ®Google Scholar
• SwainSM, BaselgaJ, MilesDet al.Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann. Oncol.25(6), 1116–1121 (2014).
   PubMed Web of Science ®Google Scholar
• MontemurroF, DelalogeS, BarriosCHet al.Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(☆). Ann. Oncol.31(10), 1350–1358 (2020).
   PubMed Web of Science ®Google Scholar
• von MinckwitzG, HuangCS, ManoMSet al.Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med.380(7), 617–628 (2019).
   PubMed Web of Science ®Google Scholar
• FarshidG, BilousM, MoreyAet al.ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. Pathology51(4), 345–348 (2019).
   PubMed Web of Science ®Google Scholar
• WolffAC, HammondMEH, AllisonKHet al.Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. J. Clin. Oncol.36(20), 2105–2122 (2018).
   PubMed Web of Science ®Google Scholar
• LiBT, MicheliniF, MisaleSet al.HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov.10(5), 674–687 (2020).
   PubMed Web of Science ®Google Scholar
• ModiS, ParkH, MurthyRKet al.Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a Phase Ib study. J. Clin. Oncol.38(17), 1887–1896 (2020).
   PubMed Web of Science ®Google Scholar
• ShitaraK, BangYJ, IwasaSet al.Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med.382(25), 2419–2430 (2020).
   PubMed Web of Science ®Google Scholar
• CutsemEV, BartolomeoMD, SmythEet al.Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Ann. Oncol.32, S1283–S1346 (2021).
   Web of Science ®Google Scholar
• HorisawaN, AdachiY, TakatsukaDet al.The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer29(2), 234–241 (2022).
   PubMed Web of Science ®Google Scholar
• SauraC, OliveiraM, FengYHet al.Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Phase III NALA trial. J. Clin. Oncol.38(27), 3138–3149 (2020).
   PubMed Web of Science ®Google Scholar
• MurthyRK, LoiS, OkinesAet al.Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N. Engl. J. Med.382(7), 597–609 (2020).
   PubMed Web of Science ®Google Scholar
• Stringer-ReasorEM, O’BrienBJ, Topletz-EricksonAet al.Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. J. Clin. Oncol.39(15), 1044 (2021).
   Web of Science ®Google Scholar
• LinNU, LeeEQ, AoyamaHet al.Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol.16(6), e270–278 (2015).
   PubMed Web of Science ®Google Scholar
• CuriglianoG, MuellerV, BorgesVet al.Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann. Oncol.33(3), 321–329 (2022).
   PubMed Web of Science ®Google Scholar
• LinNU, BorgesV, AndersCet al.Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J. Clin. Oncol.38(23), 2610–2619 (2020).
   PubMed Web of Science ®Google Scholar
• HurvitzS, KimS-B, ChungW-Pet al.Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03. Cancer Res.82, GS3-01 (2022).
   Google Scholar
• ModiS. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: plain language summary of the DESTINY-Breast01 study. Future Oncol.17(26), 3415–3423 (2021).
   PubMed Web of Science ®Google Scholar
• OgitaniY, AidaT, HagiharaKet al.DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res.22(20), 5097–5108 (2016).
   PubMed Web of Science ®Google Scholar
• OgitaniY, HagiharaK, OitateM, NaitoH, AgatsumaT. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci.107(7), 1039–1046 (2016).
   PubMed Web of Science ®Google Scholar
• JerusalemGHM, ParkYH, YamashitaTet al.Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: a subgroup analysis of the DESTINY-Breast01 trial. J. Clin. Oncol.39, 526 (2021).
   Web of Science ®Google Scholar
• BartschR, BerghoffAS, FurtnerJet al.Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: primary outcome analysis from the TUXEDO-1 trial. Ann. Oncol.33, 194 (2022).
   Web of Science ®Google Scholar
• MahajanA, AhmedS, McAleerMFet al.Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, Phase III trial. Lancet Oncol.18(8), 1040–1048 (2017).
   PubMed Web of Science ®Google Scholar
• BanderED, YuanM, ReinerASet al.Durable 5-year local control for resected brain metastases with early adjuvant SRS: the effect of timing on intended-field control. Neurooncol. Pract.8(3), 278–289 (2021).
   PubMed Web of Science ®Google Scholar
• NewmanWC, GoldbergJ, GuadixSWet al.The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. J. Neurooncol.153(3), 507–518 (2021).
   PubMed Web of Science ®Google Scholar
• WilcoxJA, BrownS, ReinerASet al.Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation. J. Neurooncol.155(3), 277–286 (2021).
   PubMed Web of Science ®Google Scholar
• LanglebenDD, SegallGM. PET in differentiation of recurrent brain tumor from radiation injury. J. Nucl. Med.41(11), 1861–1867 (2000).
   PubMed Web of Science ®Google Scholar
• OkuchiS, Rojas-GarciaA, UlyteAet al.Diagnostic accuracy of dynamic contrast-enhanced perfusion MRI in stratifying gliomas: a systematic review and meta-analysis. Cancer Med.8(12), 5564–5573 (2019).
   PubMed Web of Science ®Google Scholar
• StumpfPK, CittellyDM, RobinTPet al.Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4. Clin. Cancer Res.25(13), 3946–3953 (2019).
   PubMed Web of Science ®Google Scholar